International Conference on Malignant Lymphoma | Conference

Intensified Frontline ABVD Improves PFS in Advanced Classical Hodgkin Lymphoma

July 10th 2023

Dose-dense and dose-intense doxorubicin, bleomycin, vinblastine, dacarbazine, and granulocyte colony–stimulating factor (ABVD) generated an improvement in progression-free survival and other efficacy end points compared with PET-adapted ABVD in previously untreated patients with advanced classical Hodgkin lymphoma.

Glofitamab Monotherapy Produces Sustained Responses in Richter Syndrome

July 6th 2023

Administration of glofitamab after pretreatment with obinutuzumab provided encouraging antitumor activity with high and durable complete response rates and a manageable safety profile in heavily pretreated patients with Richter syndrome.

huCART19-IL8 Proves Safe and Elicits Durable Responses in CAR T–Pretreated R/R Lymphoma

July 3rd 2023

huCART19-IL8 had acceptable safety and induced durable responses in patients with lymphoma who were refractory or relapsed following second-generation CD19-targeted CAR T-cell therapies, according to data from a first-in-human phase 1 trial.

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27th 2023

Fixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lymphoma, according to updated data from the phase 2 GO29781 trial.

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23rd 2023

The combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter transformation, according to data from the phase 2 MOLTO trial.

Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit in Treatment-Naïve CLL

June 22nd 2023

Fixed-duration therapy with venetoclax plus obinutuzumab led to 60% reduction in the risk of progression or death compared with chlorambucil plus obinutuzumab, with benefit seen regardless of TP53 or IGHV mutation status, in previously untreated patients with chronic lymphocytic leukemia.

BrECADD Proves Noninferior to eBEACOPP in Advanced Classical Hodgkin Lymphoma

June 22nd 2023

The BrECADD combination had noninferior efficacy and superior tolerability compared with escalated BEACOPP in patients with advanced classical Hodgkin lymphoma, according to data from the phase 3 HD21 trial.

Zanubrutinib Plus Obinutuzumab and Venetoclax Induces High Undetectable MRD Rate in CLL/SLL

June 22nd 2023

Zanubrutinib plus obinutuzumab and venetoclax demonstrated lasting responses characterized by sustained progression-free survival and undetectable minimal residual disease in peripheral blood and bone marrow in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Zanubrutinib Maintains PFS Benefit With Extended Follow-Up in Previously Untreated CLL/SLL

June 21st 2023

Extended follow-up from the phase 3 SEQUOIA trial demonstrated that zanubrutinib maintained a progression-free survival benefit compared with bendamustine plus rituximab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Novel ADC Delivers Responses and a Manageable Safety Profile in R/R Non-Hodgkin Lymphoma

June 21st 2023

Zilovertamab vedotin was tolerable and generated early efficacy signals in patients with relapsed/refractory non-Hodgkin lymphoma.

Favezelimab Plus Pembrolizumab Continues to Elicit Antitumor Activity in R/R Classical Hodgkin Lymphoma

June 21st 2023

The combination of favezelimab and pembrolizumab continued to demonstrate a manageable safety profile and antitumor activity in patients with relapsed/refractory classical Hodgkin lymphoma, irrespective of whether they received prior anti–PD-1 therapy.

Study Protocol Differences May Affect BTK Inhibitor Performance in R/R CLL

June 21st 2023

Patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib in the phase 3 RESONATE trial achieved a significantly longer median progression-free survival compared with those in the phase 3 ALPINE trial, as well as a higher yet nonsignificant 2-year PFS estimate vs those in the phase 3 ELEVATE-RR trial.

Anbalcabtagene Autoleucel Generates Responses in Relapsed/Refractory LBCL

June 20th 2023

The novel, autologous, anti-CD19 CAR T-cell therapy anbalcabtagene autoleucel produced durable responses and was well tolerated in patients with relapsed/refractory large B-cell lymphoma.

Liso-Cel Elicits ORR of 97% in Relapsed/Refractory Follicular Lymphoma

June 19th 2023

A single administration of lisocabtagene maraleucel provided deep and durable remissions when used as third-line treatment in patients with relapsed or refractory follicular lymphoma, including those with high-risk features.

Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma

June 19th 2023

The CAR T-cell therapy lisocabtagene maraleucel produced rapid and durable responses in heavily pretreated patients with relapsed/refractory mantle cell lymphoma.

Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated Follicular Lymphoma, MZL

June 19th 2023

The addition of ibrutinib to bendamustine plus rituximab or R-CHOP did not lead to a statistically significant improvement in progression-free survival vs either chemoimmunotherapy regimen alone in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma.

Duvelisib Demonstrates Higher Activity in Angioimmunoblastic Peripheral T-Cell Lymphoma

June 15th 2023

Treatment with duvelisib led to a high response rate in patients with peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma.

Concurrent Ibrutinib With CAR T-Cell Therapy Improves ORR, Reduces Severe CRS in High-Risk CLL

June 22nd 2019

Patients with high-risk relapsed/refractory chronic lymphocytic leukemia who failed or were intolerant of ibrutinib derived more benefit from CD19‐targeted CAR T-cell therapy when the BTK inhibitor was concurrently administered than when it was not.

Dr. Siddiqi on CAR T-Cell Therapy in Relapsed/Refractory CLL/SLL

June 21st 2019

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Nivolumab/Brentuximab Vedotin Combo Is Highly Active in Relapsed/Refractory PMBCL

June 21st 2019

Nearly three-fourths of patients with relapsed/refractory primary mediastinal large B-cell lymphoma responded to a combination of nivolumab (Opdivo) plus brentuximab vedotin (Adcetris).